BridgeBio Oncology Therapeutics
$8.56
0
+$0.25+3.01% Friday 20:00
+$0.00+0%Friday 20:00After hours
Statistics
Day High
8.6
Day Low
8.55
52W High
14.87
52W Low
7
Volume
14,574
Avg. Volume
-
Mkt Cap
685.08M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
2SepExpected
Q2 2025
Q3 2025
Q1 2026
Next
-49.62
-33.2
-16.79
-0.38
Expected EPS
-0.560909
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-134.04MNet Income
Analyst Ratings
24.80Average Price Target
The highest estimate is 29.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow BBOT. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Show more...
CEO
Dr. Neil Kumar Ph.D.
Employees
92
Country
Cayman Islands
ISIN
US1079241022
Listings
0 Comments
Share your thoughts
FAQ
What is BridgeBio Oncology Therapeutics stock price today?▼
The current price of BBOT is $8.56 USD — it has increased by +3.01% in the past 24 hours. Watch BridgeBio Oncology Therapeutics stock price performance more closely on the chart.
What is BridgeBio Oncology Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange BridgeBio Oncology Therapeutics stocks are traded under the ticker BBOT.
What is BridgeBio Oncology Therapeutics market cap?▼
Today BridgeBio Oncology Therapeutics has the market capitalization of 685.08M
When is the next BridgeBio Oncology Therapeutics earnings date?▼
BridgeBio Oncology Therapeutics is going to release the next earnings report on September 02, 2026.
What were BridgeBio Oncology Therapeutics earnings last quarter?▼
BBOT earnings for the last quarter are -0.53 USD per share, whereas the estimation was -0.51 USD resulting in a -2.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is BridgeBio Oncology Therapeutics revenue for the last year?▼
BridgeBio Oncology Therapeutics revenue for the last year amounts to 0 USD.
What is BridgeBio Oncology Therapeutics net income for the last year?▼
BBOT net income for the last year is -134.04M USD.
How many employees does BridgeBio Oncology Therapeutics have?▼
As of July 20, 2026, the company has 92 employees.
In which sector is BridgeBio Oncology Therapeutics located?▼
BridgeBio Oncology Therapeutics operates in the Health & Wellness sector.
When did BridgeBio Oncology Therapeutics complete a stock split?▼
BridgeBio Oncology Therapeutics has not had any recent stock splits.
Where is BridgeBio Oncology Therapeutics headquartered?▼
BridgeBio Oncology Therapeutics is headquartered in South San Francisco, Cayman Islands.